Fate Therapeutics, Inc. (FATE)

Market Cap	363.27M
Revenue (ttm)	12.32M
Net Income (ttm)	-175.72M
Shares Out	113.88M
EPS (ttm)	-1.70
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	607,710
Open	3.140
Previous Close	3.150
Day's Range	3.080 - 3.240
52-Week Range	1.630 - 8.830
Beta	1.84
Analysts	Buy
Price Target	6.70 (+110.03%)
Earnings Date	Nov 6, 2024

About FATE

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company’s chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 1, 2013
• Employees: 181
• Stock Exchange: NASDAQ
• Ticker Symbol: FATE
• Website: https://www.fatetherapeutics.com

Financial Performance

In 2023, Fate Therapeutics's revenue was $63.53 million, a decrease of -34.03% compared to the previous year's $96.30 million. Losses were -$160.93 million, -42.88% less than in 2022.

Analyst Forecast

According to 12 analysts, the average rating for FATE stock is "Buy." The 12-month stock price forecast is $6.7, which is an increase of 110.03% from the latest price.

Price Target

$6.7

(110.03% upside)

Analyst Consensus: Buy